Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 14/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.34 |
| ▸ | MGAM | O43451 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 2/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4346820 | 0.86 | PTGER1 (0.40) | PTGER1CSNK1DCSNK1E | |
| SCHEMBL4328987 | 0.83 | CTSA (0.41) | CTSAPTGER1 | |
| SCHEMBL4340947 | 0.78 | PTGER1 (0.36) | PTGER1CSNK1DCSNK1E | |
| SCHEMBL4341004 | 0.78 | PTGER1 (0.36) | PTGER1CSNK1DCSNK1E | |
| SCHEMBL4334945 | 0.76 | CSNK1E (0.38) | PTGER1CSNK1DCSNK1E | |
| SCHEMBL4339201 | 0.76 | JAK2 (0.38) | PTGER1CSNK1DCSNK1E | |
| SCHEMBL4334500 | 0.76 | SRC (0.35) | CTSA | |
| SCHEMBL4329361 | 0.74 | CYP1A2 (0.37) | PTGER1 | |
| SCHEMBL4335815 | 0.69 | PIK3CD (0.35) | CTSA | |
| SCHEMBL4341005 | 0.69 | CSNK1E (0.34) | PTGER1CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | CTSA 4048/4885PTGER1 3143/4885CSNK1D 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.